Arrowhead Pharmaceuticals (ARWR) Shares Up 11.8%

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shot up 11.8% during trading on Thursday . The company traded as high as $14.23 and last traded at $14.22. 2,675,345 shares were traded during trading, an increase of 29% from the average session volume of 2,067,891 shares. The stock had previously closed at $12.72.

A number of research firms have recently commented on ARWR. William Blair restated an “outperform” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 17th. Chardan Capital set a $25.00 target price on Arrowhead Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, October 14th. Cantor Fitzgerald restated a “buy” rating and set a $24.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, October 11th. BidaskClub cut Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, October 6th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $25.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, October 4th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $21.45.

The company has a quick ratio of 8.69, a current ratio of 8.69 and a debt-to-equity ratio of 0.02. The stock has a market cap of $1.10 billion, a P/E ratio of -30.26 and a beta of 1.75.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.01. Arrowhead Pharmaceuticals had a negative return on equity of 59.39% and a negative net margin of 400.13%. The company had revenue of $0.73 million for the quarter, compared to analysts’ expectations of $0.62 million. As a group, research analysts forecast that Arrowhead Pharmaceuticals Inc will post -0.65 EPS for the current year.

In related news, CFO Kenneth Allen Myszkowski sold 45,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Thursday, September 6th. The stock was sold at an average price of $19.34, for a total value of $870,300.00. Following the sale, the chief financial officer now directly owns 335,815 shares in the company, valued at approximately $6,494,662.10. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Christopher Richard Anzalone sold 164,834 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $14.45, for a total value of $2,381,851.30. Following the completion of the sale, the chief executive officer now owns 1,868,789 shares in the company, valued at $27,004,001.05. The disclosure for this sale can be found here. Over the last quarter, insiders sold 440,971 shares of company stock worth $6,466,189. 4.60% of the stock is currently owned by insiders.

Hedge funds have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Arrowhead Pharmaceuticals in the 2nd quarter worth about $100,000. Great West Life Assurance Co. Can acquired a new stake in Arrowhead Pharmaceuticals in the 2nd quarter worth about $106,000. Macquarie Group Ltd. acquired a new stake in Arrowhead Pharmaceuticals in the 2nd quarter worth about $151,000. Amalgamated Bank acquired a new stake in Arrowhead Pharmaceuticals in the 2nd quarter worth about $181,000. Finally, Legal & General Group Plc acquired a new stake in Arrowhead Pharmaceuticals in the 2nd quarter worth about $188,000. Institutional investors own 59.43% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.

Read More: Stock Symbol

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply